Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study
, Toshihiko Torigoe 5, Gabriela Bindea 1,2,3, Boryana Popivanova 6, Mingli Xu 6, Tomonobu Fujita 6, Shoichi Hazama 7, Nobuaki Suzuki 8, Hiroaki Nagano 8, Kiyotaka Okuno 9, Yoshihiko Hirohashi 5, Tomohisa Furuhata 10, Ichiro Takemasa 10, Prabhudas Patel 11, Hemangini Vora 11, Birva Shah 11, Jayendrakumar B. Patel 11, Kruti N. Rajvik 11, Shashank J. Pandya 11, Shilin N. Shukla 11, Jiun-Kae Jack Lee 17, Tilman T. Rau 16, Susanne Merkel 21, Marc Van den Eynde 22,23, Linh T. Nguyen 31, SeongJun Han 31, Giuseppe V. Masucci 32, Emilia Andersson 32, Michal Vocka 33, Jan Spacek 33, Kristyna Nemejcova 34, Fabiana Tatangelo 35, Luigi Laghi 39,40, Fabio Grizzi 41,42, Dragos-Viorel Scripcariu 47, Francesco M. Marincola 48, add
Show full author list
Round 1
Reviewer 1 Report
The authors provide a very nice study about Immunoscore in a subset of Asian patients with colon cancer. Two main remarks:
- Is there a reason the 3-category panel was not checked for MSS cancers?
- It is important to highlight the use of adjuvant chemotherapy and its association with survival.
- If possible, mention any correlation with circulating tumor dna assays if the patients had this done too.
Author Response
Dear reviewer,
Thank you for the careful review of our manuscript that we are submitting to Cancers. We haven taken your comments into consideration and made the necessary modifications to the manuscript. Please find in attachment our answers to your questions.
Best regards.
Jerome Galon.
Author Response File: 
Author Response.pdf
Reviewer 2 Report
Mlecnik, B et al.: Clinical performance of the consensus Immunoscore in colon cancer in the Asian population from the multicenter international SITC study
Journal: Cancers. (MS No. Cancers-1861185)
The authors demonstrated that a high-Immunocore is significantly associated with prolonged survival of colon cancer patients within the Asian population like that of the European population. This analysis will be of great clinical benefit because it will allow us to select a subset of Stage 3 colorectal cancer patients who will require adjuvant chemotherapy.　The paper was also analyzed and concluded for a cohort of patients from an independent hospital, so the results obtained are very robust.　This journal has been concluded with excellent analyses of independent institutes.However, there are some points left that require clarification before the manuscript can be considered suitable for publication.
Minor issues:
1. The authors only analyzed MSS tumors. How about Immunocore in MSI-H tumors? Even if there is no difference, the authors should show the results.
2. The original photos of the Immunocore on digital slides should be presented because this information will provide evidence to make a clinical decision.
Author Response
Dear reviewer,
We would like to thank you for your careful review of our manuscript that we are submitting to Cancers. We have taken into consideration your comments and suggestions and made the necessary modifications to the manuscript.
Please find in attachment our answers to your questions.
Best regards.
Jerome Galon
Author Response File: Author Response.pdf
